Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier?

Journal of Bioenergetics and Biomembranes

Volumn 47, Issue 1-2, 2015, Pages 111-118

  Jaber, Sausan ^a   Polster, Brian M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Coenzyme Q10; Complex I; Friedreich s ataxia; Mitochondria; NQO1; Quinone

Indexed keywords

IDEBENONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TRANSCRIPTION FACTOR NRF2; ANTIOXIDANT; NEUROPROTECTIVE AGENT; NQO1 PROTEIN, HUMAN; OXIDIZING AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UBIQUINOL CYTOCHROME C REDUCTASE; UBIQUINONE;

ANTIOXIDANT ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; CELL PROTECTION; CELLS BY BODY ANATOMY; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; ELECTRON TRANSPORT; GLIA CELL; HUMAN; MITOCHONDRION; NERVE CELL; NEUROPROTECTION; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVIEW; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; METABOLISM; OXIDATION REDUCTION REACTION;

ANIMALS; ANTIOXIDANTS; ELECTRON TRANSPORT COMPLEX I; ELECTRON TRANSPORT COMPLEX III; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); NEUROPROTECTIVE AGENTS; OXIDANTS; OXIDATION-REDUCTION; UBIQUINONE;

EID: 84925491335     PISSN: 0145479X     EISSN: 15736881     Source Type: Journal    
DOI: 10.1007/s10863-014-9571-y     Document Type: Review

References (84)

1. Ahlgren-Beckendorf JA, Reising AM, Schander MA, Herdler JW, Johnson JA (1999) Coordinate regulation of NAD (P) H:quinone oxidoreductase and glutathione-S-transferases in primary cultures of rat neurons and glia: role of the antioxidant/electrophile responsive element. Glia 25:131–142
2. Bell KF, Al-Mubarak B, Fowler JH, Baxter PS, Gupta K, Tsujita T, Chowdhry S, Patani R, Chandran S, Horsburgh K, Hayes JD, Hardingham GE (2011) Mild oxidative stress activates Nrf2 in astrocytes, which contributes to neuroprotective ischemic preconditioning. Proc Natl Acad Sci U S A 108:E1–E2
3. Bergamasco B, Scarzella L, La CP (1994) Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. Funct Neurol 9:161–168
4. Beyer RE, Segura AJ, Di BS, Cavazzoni M, Fato R, Fiorentini D, Galli MC, Setti M, Landi L, Lenaz G (1996) The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc Natl Acad Sci U S A 93:2528–2532
5. Briere JJ, Schlemmer D, Chretien D, Rustin P (2004) Quinone analogues regulate mitochondrial substrate competitive oxidation. Biochem Biophys Res Commun 316:1138–1142
6. Bruno V, Battaglia G, Copani A, Sortino MA, Canonico PL, Nicoletti F (1994) Protective action of idebenone against excitotoxic degeneration in cultured cortical neurons. Neurosci Lett 178:193–196
7. Cardoso SM, Pereira C, Oliveira CR (1998) The protective effect of vitamin E, idebenone and reduced glutathione on free radical mediated injury in rat brain synaptosomes. Biochem Biophys Res Commun 246:703–710
8. Chan TS, Teng S, Wilson JX, Galati G, Khan S, O’brien PJ (2002) Coenzyme Q cytoprotective mechanisms for mitochondrial complex I cytopathies involves NAD (P) H: quinone oxidoreductase 1 (NQO1). Free Radic Res 36:421–427
9. Conover TE, Ernster L (1962) DT diaphorase. II. relation to respiratory chain of intact mitochondira. Biochim Biophys Acta 58:189–200
10. Cooper JM, Schapira AH (2003) Friedreich’s Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapy. Biofactors 18:163–171
11. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH (2007) Neurological effects of high-dose idebenone in patients with Friedreich’s ataxia: a randomised, placebo-controlled trial. Lancet Neurol 6:878–886
12. Dinkova-Kostova AT, Talalay P (2010) NAD (P) H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys 501:116–123
13. Dong H, Shertzer HG, Genter MB, Gonzalez FJ, Vasiliou V, Jefcoate C, Nebert DW (2013) Mitochondrial targeting of mouse NQO1 and CYP1B1 proteins. Biochem Biophys Res Commun 435:727–732
14. Dragan M, Dixon SJ, Jaworski E, Chan TS, O’brien PJ, Wilson JX (2006) Coenzyme Q (1) depletes NAD (P) H and impairs recycling of ascorbate in astrocytes. Brain Res 1078:9–18
15. Erb M, Hoffmann-Enger B, Deppe H, Soeberdt M, Haefeli RH, Rummey C, Feurer A, Gueven N (2012) Features of idebenone and related short-chain quinones that rescue ATP levels under conditions of impaired mitochondrial complex I. PLoS One 7:e36153
16. Esposti MD, Ngo A, Ghelli A, Benelli B, Carelli V, McLennan H, Linnane AW (1996) The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria. Arch Biochem Biophys 330:395–400
17. Fash DM, Khdour OM, Sahdeo SJ, Goldschmidt R, Jaruvangsanti J, Dey S, Arce PM, Collin VC, Cortopassi GA, Hecht SM (2013) Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection. Bioorg Med Chem 21:2346–2354, S0968-0896 (13) 00125-9
18. Fato R, Bergamini C, Leoni S, Lenaz G (2008) Mitochondrial production of reactive oxygen species: role of complex I and quinone analogues. Biofactors 32:31–39
19. Genova ML, Ventura B, Giuliano G, Bovina C, Formiggini G, Parenti CG, Lenaz G (2001) The site of production of superoxide radical in mitochondrial complex I is not a bound ubisemiquinone but presumably iron-sulfur cluster N2. FEBS Lett 505:364–368
20. Genova ML, Pich MM, Biondi A, Bernacchia A, Falasca A, Bovina C, Formiggini G, Parenti CG, Lenaz G (2003) Mitochondrial production of oxygen radical species and the role of Coenzyme Q as an antioxidant. Exp Biol Med Maywood 228:506–513
21. Geromel V, Darin N, Chretien D, Benit P, DeLonlay P, Rotig A, Munnich A, Rustin P (2002) Coenzyme Q (10) and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits. Mol Genet Metab 77:21–30
22. Giorgio V, Petronilli V, Ghelli A, Carelli V, Rugolo M, Lenaz G, Bernardi P (2012) The effects of idebenone on mitochondrial bioenergetics. Biochim Biophys Acta 1817:363–369
23. Greco T, Fiskum G (2010) Neuroprotection through stimulation of mitochondrial antioxidant protein expression. J Alzheimers Dis 20(Suppl 2):S427–S437
24. Gutzmann H, Hadler D (1998) Sustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease: update on a 2-year double-blind multicentre study. J Neural Transm Suppl 54:301–310
25. Gutzmann H, Kuhl KP, Hadler D, Rapp MA (2002) Safety and efficacy of idebenone versus tacrine in patients with Alzheimer’s disease: results of a randomized, double-blind, parallel-group multicenter study. Pharmacopsychiatry 35:12–18
26. Habas A, Hahn J, Wang X, Margeta M (2013) Neuronal activity regulates astrocytic Nrf2 signaling. Proc Natl Acad Sci U S A 110:18291–18296
27. Haefeli RH, Erb M, Gemperli AC, Robay D, Courdier FI, Anklin C, Dallmann R, Gueven N (2011) NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. PLoS One 6:e17963
28. Heitz FD, Erb M, Anklin C, Robay D, Pernet V, Gueven N (2012) Idebenone protects against retinal damage and loss of vision in a mouse model of Leber’s hereditary optic neuropathy. PLoS One 7:e45182
29. Imada I, Fujita T, Sugiyama Y, Okamoto K, Kobayashi Y (1989) Effects of idebenone and related compounds on respiratory activities of brain mitochondria, and on lipid peroxidation of their membranes. Arch Gerontol Geriatr 8:323–341
30. Imada I, Sato EF, Kira Y, Inoue M (2008) Effect of CoQ homologues on reactive oxygen generation by mitochondria. Biofactors 32:41–48
31. Joseph P, Jaiswal AK (1994) NAD (P) H:quinone oxidoreductase1 (DT diaphorase) specifically prevents the formation of benzo [a] pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc Natl Acad Sci U S A 91:8413–8417
32. Kalen A, Norling B, Appelkvist EL, Dallner G (1987) Ubiquinone biosynthesis by the microsomal fraction from rat liver. Biochim Biophys Acta 926:70–78
33. Kim J, Lee S, Shim J, Kim HW, Kim J, Jang YJ, Yang H, Park J, Choi SH, Yoon JH, Lee KW, Lee HJ (2012) Caffeinated coffee, decaffeinated coffee, and the phenolic phytochemical chlorogenic acid up-regulate NQO1 expression and prevent H (2) O (2)-induced apoptosis in primary cortical neurons. Neurochem Int 60:466–474
34. Kim J, Kim SK, Kim HK, Mattson MP, Hyun DH (2013) Mitochondrial function in human neuroblastoma cells Is up-regulated and protected by NQO1, a plasma membrane redox enzyme. PLoS One 8:e69030
35. King MS, Sharpley MS, Hirst J (2009) Reduction of hydrophilic ubiquinones by the flavin in mitochondrial NADH:ubiquinone oxidoreductase (complex I) and production of reactive oxygen species. Biochemistry 48:2053–2062
36. Kowaltowski AJ, Castilho RF, Vercesi AE (2001) Mitochondrial permeability transition and oxidative stress. FEBS Lett 495:12–15
37. Kraft AD, Johnson DA, Johnson JA (2004) Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci 24:1101–1112
38. Kutz K, Drewe J, Vankan P (2009) Pharmacokinetic properties and metabolism of idebenone. J Neurol 256(Suppl 1):31–35
39. Li W, Kong AN (2009) Molecular mechanisms of Nrf2-mediated antioxidant response. Mol Carcinog 48:91–104
40. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787–795
41. Lind C, Hochstein P, Ernster L (1982) DT-diaphorase as a quinone reductase: a cellular control device against semiquinone and superoxide radical formation. Arch Biochem Biophys 216:178–185
42. Lopez LC, Quinzii CM, Area E, Naini A, Rahman S, Schuelke M, Salviati L, Dimauro S, Hirano M (2010) Treatment of CoQ (10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: time- and compound-dependent effects. PLoS One 5:e11897
43. Lynch DR, Perlman SL, Meier T (2010) A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch Neurol 67:941–947
44. Meier T, Buyse G (2009) Idebenone: an emerging therapy for Friedreich ataxia. J Neurol 256(Suppl 1):25–30
45. Meier T, Perlman SL, Rummey C, Coppard NJ, Lynch DR (2012) Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich’s ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J Neurol 259:284–291
46. Miyamoto M, Coyle JT (1990) Idebenone attenuates neuronal degeneration induced by intrastriatal injection of excitotoxins. Exp Neurol 108:38–45
47. Miyamoto M, Murphy TH, Schnaar RL, Coyle JT (1989) Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line. J Pharmacol Exp Ther 250:1132–1140
48. Mordente A, Martorana GE, Minotti G, Giardina B (1998) Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone). Chem Res Toxicol 11:54–63
49. Murphy TH, Schnaar RL, Coyle JT (1990) Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB J 4:1624–1633
50. Murphy TH, Yu J, Ng R, Johnson DA, Shen H, Honey CR, Johnson JA (2001) Preferential expression of antioxidant response element mediated gene expression in astrocytes. J Neurochem 76:1670–1678
51. Nagai Y, Yoshida K, Narumi S, Tanayama S, Nagaoka A (1989) Brain distribution of idebenone and its effect on local cerebral glucose utilization in rats. Arch Gerontol Geriatr 8:257–272
52. Nagaoka A, Suno M, Shibota M, Kakihana M (1989) Effects of idebenone on neurological deficits, local cerebral blood flow, and energy metabolism in rats with experimental cerebral ischemia. Arch Gerontol Geriatr 8:193–202
53. Nicholls DG, Ferguson SJ (2013) Bioenergetics 4. Academic, London
54. O’Brien PJ (1991) Molecular mechanisms of quinone cytotoxicity. Chem Biol Interact 80:1–41
55. Ohnishi ST, Ohnishi T, Muranaka S, Fujita H, Kimura H, Uemura K, Yoshida K, Utsumi K (2005) A possible site of superoxide generation in the complex I segment of rat heart mitochondria. J Bioenerg Biomembr 37:1–15
56. Parkinson MH, Schulz JB, Giunti P (2013) Co-enzyme Q10 and idebenone use in Friedreich’s ataxia. J Neurochem 126(Suppl 1):125–141
57. Pereira CF, Oliveira CR (2000) Oxidative glutamate toxicity involves mitochondrial dysfunction and perturbation of intracellular Ca2+ homeostasis. Neurosci Res 37:227–236
58. Petronilli V, Costantini P, Scorrano L, Colonna R, Passamonti S, Bernardi P (1994) The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols. Increase of the gating potential by oxidants and its reversal by reducing agents. J Biol Chem 269:16638–16642
59. Raina AK, Templeton DJ, Deak JC, Perry G, Smith MA (1999) Quinone reductase (NQO1), a sensitive redox indicator, is increased in Alzheimer’s disease. Redox Rep 4:23–27
60. Ranen NG, Peyser CE, Coyle JT, Bylsma FW, Sherr M, Day L, Folstein MF, Brandt J, Ross CA, Folstein SE (1996) A controlled trial of idebenone in Huntington’s disease. Mov Disord 11:549–554
61. Ratan RR, Murphy TH, Baraban JM (1994) Oxidative stress induces apoptosis in embryonic cortical neurons. J Neurochem 62:376–379
62. Rauchova H, Drahota Z, Bergamini C, Fato R, Lenaz G (2008) Modification of respiratory-chain enzyme activities in brown adipose tissue mitochondria by idebenone (hydroxydecyl-ubiquinone). J Bioenerg Biomembr 40:85–93
63. Rotig A, De LP, Chretien D, Foury F, Koenig M, Sidi D, Munnich A, Rustin P (1997) Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 17:215–217
64. SantaCruz KS, Yazlovitskaya E, Collins J, Johnson J, DeCarli C (2004) Regional NAD (P) H:quinone oxidoreductase activity in Alzheimer’s disease. Neurobiol Aging 25:63–69
65. Satoh T, Okamoto SI, Cui J, Watanabe Y, Furuta K, Suzuki M, Tohyama K, Lipton SA (2006) Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic phase II inducers. Proc Natl Acad Sci U S A 103:768–773
66. Satoh T, Kosaka K, Itoh K, Kobayashi A, Yamamoto M, Shimojo Y, Kitajima C, Cui J, Kamins J, Okamoto S, Izumi M, Shirasawa T, Lipton SA (2008) Carnosic acid, a catechol-type electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1. J Neurochem 104:1116–1131
67. Schinzel AC, Takeuchi O, Huang Z, Fisher JK, Zhou Z, Rubens J, Hetz C, Danial NN, Moskowitz MA, Korsmeyer SJ (2005) Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc Natl Acad Sci U S A 102:12005–12010
68. Schultzberg M, Segura-Aguilar J, Lind C (1988) Distribution of DT diaphorase in the rat brain: biochemical and immunohistochemical studies. Neurosci 27:763–776
69. Senin U, Parnetti L, Barbagallo-Sangiorgi G, Bartorelli L, Bocola V, Capurso A, Cuzzupoli M, Denaro M, Marigliano V, Tammaro AE, Fioravanti M (1992) Idebenone in senile dementia of Alzheimer type: a multicentre study. Arch Gerontol Geriatr 15:249–260
70. Sherer TB, Richardson JR, Testa CM, Seo BB, Panov AV, Yagi T, Matsuno-Yagi A, Miller GW, Greenamyre JT (2007) Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson’s disease. J Neurochem 100:1469–1479
71. Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA, Murphy TH (2003) Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 23:3394–3406
72. Siegel D, Ross D (2000) Immunodetection of NAD (P) H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 29:246–253
73. Stringer JL, Gaikwad A, Gonzales BN, Long DJ Jr, Marks LM, Jaiswal AK (2004) Presence and induction of the enzyme NAD (P) H: quinone oxidoreductase 1 in the central nervous system. J Comp Neurol 471:289–297
74. Suno M, Nagaoka A (1984a) Inhibition of lipid peroxidation by a novel compound, idebenone (CV-2619). Jpn J Pharmacol 35:196–198
75. Suno M, Nagaoka A (1984b) Inhibition of lipid peroxidation by a novel compound (CV-2619) in brain mitochondria and mode of action of the inhibition. Biochem Biophys Res Commun 125:1046–1052
76. Suno M, Nagaoka A (1989) Inhibition of lipid peroxidation by idebenone in brain mitochondria in the presence of succinate. Arch Gerontol Geriatr 8:291–297
77. Tai KK, Pham L, Truong DD (2011) Idebenone induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells. Neurotox Res 20:321–328
78. Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, Weiner MF, Zamrini E, Thomas RG (2003) Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease. Neurology 61:1498–1502
79. Torii H, Yoshida K, Kobayashi T, Tsukamoto T, Tanayama S (1985) Disposition of idebenone (CV-2619), a new cerebral metabolism improving agent, in rats and dogs. J Pharmacobiodyn 8:457–467
80. van Muiswinkel FL, de Vos RA, Bol JG, Andringa G, Jansen Steur EN, Ross D, Siegel D, Drukarch B (2004) Expression of NAD (P) H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol Aging 25:1253–1262
81. Wang Y, Santa-Cruz K, DeCarli C, Johnson JA (2000) NAD (P) H:quinone oxidoreductase activity is increased in hippocampal pyramidal neurons of patients with Alzheimer’s disease. Neurobiol Aging 21:525–531
82. Weyer G, Babej-Dolle RM, Hadler D, Hofmann S, Herrmann WM (1997) A controlled study of 2 doses of idebenone in the treatment of Alzheimer’s disease. Neuropsychobiology 36:73–82
83. Wong A, Yang J, Cavadini P, Gellera C, Lonnerdal B, Taroni F, Cortopassi G (1999) The Friedreich’s ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol Genet 8:425–430
84. Yamada K, Tanaka T, Han D, Senzaki K, Kameyama T, Nabeshima T (1999) Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo. Eur J Neurosci 11:83–90